(MENAFN- Baystreet)
NCR Loses on Amex Connection
Quest Descends on Release of Test Launch
Chrysler Parent Takes Wraps off Halcyon
Coca-Cola Posts Mixed
earnings Due To Lower Sales Volumes
Arm Holdings' Stock Rises 99% In Past Five Days Previous Articles Subscribe to Get Small Cap News & Alerts
Glenn Wilkin - Tuesday, February 13, 2024
Biogen Staggers on Q4 Figures
Biogen (NASDAQ:BIIB) shares lost ground on Tuesday. This, after the company reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category.
Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. It reported net income of $249.7 billion, or $1.71 per share, for the fourth quarter, down from net income of $550.4 billion, or $3.79 per share, for the same period a year ago. Adjusting for one-time items, the company reported $2.95 per share.
The drugmaker's fourth-quarter earnings per share, both unadjusted and adjusted, saw a negative impact of 35 cents associated with previously disclosed costs of pulling Aduhelm, which had a polarizing approval and rollout in the U.S.
Biogen is cutting costs while pinning its hopes on its other Alzheimer's drugs, including its closely watched treatment Leqembi, and other newly launched products to replace declining revenue from its multiple sclerosis therapies.
In the fourth quarter, Biogen reported earnings per share of $2.95 adjusted, as opposed to the expected $3.18, on revenue of $2.39 billion vs. $2.47 billion expected.
Also on Tuesday, Biogen issued full-year 2024 guidance that calls for adjusted earnings of $15 to $16 per share. Analysts had expected full-year earnings guidance of $15.65 per share.
BIIB shares stumbled $12.12, or 5%, to $232.62.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN13022024000212011056ID1107846795
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.